Clinical Trial Update: Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease [NA]

View source ↗

Summary

A clinical trial investigating short-term endogenous hydrogen sulfide upregulation for vein graft disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vein Graft Disease

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Vascular Diseases, Surgery | NA | Status: WITHDRAWN